APYX Q2 2024: Handpiece Sales Surge 20%+ as Generator Headwinds Persist
APYX’s handpiece sales rose over 20% globally, offsetting persistent weakness in capital equipment demand. The company’s OEM segment outperformed expectations but gross margin and profitability declined due to mix shift and higher interest expense. Updated guidance reflects continued capital equipment headwinds, with handpiece growth and cost discipline as key levers for navigating the challenging aesthetic market.
Summary
- Handpiece Growth Offsets Generator Weakness: Double-digit handpiece sales expansion is mitigating sluggish capital equipment demand.
- OEM Outperformance Shifts Margin Profile: Strong OEM sales mix contributed to lower gross margin despite cost controls.
- Guidance Anchored on Cost Cuts and Handpiece Momentum: Leadership signals further discipline while relying on recurring handpiece revenue to stabilize results.
Business Overview
APYX Medical develops and markets advanced energy-based medical devices, primarily for cosmetic surgery and body contouring. The company’s core product is Renuvion, a cold atmospheric plasma system used for tissue contraction and coagulation, sold as both capital equipment (generators) and recurring-use handpieces. Revenue is split between the Advanced Energy segment, which includes Renuvion sales, and the OEM segment, which produces devices for other medical companies. The business model relies on initial generator placements followed by ongoing handpiece sales, with OEM providing diversification and incremental growth.
Performance Analysis
APYX’s Q2 revenue fell 10% year over year to $12.1 million, with Advanced Energy sales down 17% and OEM up 29%. The handpiece business was the clear bright spot, growing over 20% globally and helping to offset a sharp drop in generator sales driven by continued capital equipment purchasing delays. This dynamic reinforces the importance of the consumable handpiece model, which provides recurring revenue even as macro pressures weigh on capital budgets.
Gross profit margin contracted to 61.7% from 68.4%, primarily due to a higher mix of lower-margin OEM sales and increased international sales within Advanced Energy. Operating expenses were down modestly, reflecting ongoing cost discipline, but higher interest expense and the absence of a prior-year property sale gain pushed the net loss higher. Cash burn improved slightly on better working capital, but the company’s cash balance fell to $32.7 million.
- Handpiece Sales Drive Resilience: Both US and international handpiece sales grew over 20%, demonstrating broad-based demand.
- OEM Mix Dilutes Margins: OEM’s outperformance contributed to a lower overall gross margin profile, highlighting the tradeoff between top-line stability and profitability.
- Cost Controls Cushion Downside: Operating expenses declined year over year, helping to partially offset revenue softness and margin pressure.
Despite the persistent capital equipment headwinds, APYX’s recurring handpiece revenue and OEM diversification are providing a degree of stability. However, profit pressure and cash burn remain key investor watchpoints as the company navigates the current environment.
Executive Commentary
"In spite of this challenging environment, we were pleased to drive strong growth in sales of our handpieces, fueled by demand from our global base of customers as well as new users. Handpiece sales to customers in both the US and international markets increased by more than 20% year over year, helping to mitigate the impact of lower generator sales as anticipated."
Charlie Goodwin, President and Chief Executive Officer
"Gross profit margin was 61.7% compared to 68.4% in the prior period. The decrease in our gross margin was driven primarily by changes in the sales mix between our two segments with our OEM segment comprising a higher percentage of total sales and geographic mix within our advanced energy segment with international sales comprising a higher percentage of total sales compared to the prior period."
Matt Hill, Chief Financial Officer
Strategic Positioning
1. Recurring Handpiece Revenue as Core Stabilizer
The handpiece business, a recurring consumables model, is proving essential for APYX’s resilience. With over 20% growth in both US and international markets, handpiece sales are offsetting the unpredictable timing of generator purchases. This recurring revenue stream is increasingly central as capital budgets remain constrained.
2. OEM Segment Provides Diversification, but at a Margin Cost
OEM sales surged 29% and exceeded expectations, providing a buffer against Advanced Energy volatility. However, the lower-margin nature of OEM dilutes overall profitability. Management is leveraging this segment to smooth revenue, but margin tradeoffs are evident and must be managed carefully.
3. Clinical Evidence and Market Education as Adoption Levers
APYX is investing in clinical research and surgeon education to support Renuvion’s adoption. Over 90 published studies and new peer-reviewed data reinforce safety and efficacy, while hands-on programs and DTC campaigns expand awareness. These efforts are designed to drive both near-term handpiece utilization and longer-term generator adoption as macro conditions improve.
4. Cost Discipline and Cash Efficiency
Operating expense reductions and working capital improvements are helping to manage cash burn amid revenue pressure. Leadership is signaling ongoing vigilance on expenses, with an eye toward optimizing cash runway while sustaining commercial and R&D investment.
5. Geographic Expansion Opportunities Remain on Horizon
APYX is pursuing registration in South Korea and China, two major untapped markets. While timing remains uncertain, successful entry could provide a future growth lever as global demand for body contouring rises.
Key Considerations
This quarter highlighted APYX’s ability to leverage its recurring revenue streams and cost controls to partially offset sector-wide capital equipment weakness. The company’s strategic priorities center on maximizing handpiece utilization, prudent expense management, and deepening clinical differentiation, while monitoring the timing of macro recovery and new market entry.
Key Considerations:
- Handpiece Utilization Drives Stability: Recurring sales are crucial for navigating capital equipment cycles and provide a foundation for future growth.
- OEM Growth Is a Double-Edged Sword: While it supports revenue, the margin impact requires careful management and transparency.
- Seasonality and Macro Remain Material: Q3 is expected to be seasonally softer, with Q4 typically stronger, but macro headwinds persist.
- Cash Burn and Profitability Under Scrutiny: Improved working capital helps, but continued losses and declining cash reserves are key investor risks.
Risks
Persistent capital equipment softness, especially in the US, remains the primary risk, with management assuming no near-term recovery. Margin pressure from sales mix shifts, higher interest expense, and ongoing cash burn could constrain flexibility if the macro environment remains weak. Geographic expansion is a potential upside, but timing and regulatory hurdles add uncertainty. Investors should monitor for further erosion in generator demand or slower handpiece growth, as well as any delays in new market launches.
Forward Outlook
For Q3, APYX expects:
- Seasonally softer revenue in Advanced Energy due to summer vacations.
- OEM revenue to normalize after a strong Q2.
For full-year 2024, management updated guidance:
- Total revenue of $50.6 million to $52.1 million (down 3% to flat YoY).
- Advanced Energy revenue of $41.6 million to $43.1 million (down 4% to up 1%).
- OEM revenue of approximately $9 million (up 1%).
- Net loss of $24.5 million to $23.5 million, improved from prior guidance.
- Cash used in operations of approximately $21 million for the year.
Management emphasized that handpiece growth and cost controls are expected to offset generator softness, with Q4 typically providing a seasonal lift. The team continues to focus on education, clinical validation, and new market registrations as future growth drivers.
Takeaways
APYX’s Q2 demonstrates the value of a recurring revenue base in a challenged capital cycle, but margin and cash burn trends warrant close investor attention.
- Handpiece Outperformance: Recurring handpiece sales are the most reliable growth engine and will remain the key stabilizer as capital headwinds persist.
- OEM Tradeoff: OEM’s revenue contribution is positive for top-line but dilutes margin, requiring ongoing optimization and transparency.
- Macro and Market Entry Watch: Investors should watch for signs of capital equipment demand recovery and any news on South Korea or China market entry as potential inflection points.
Conclusion
APYX is navigating a tough capital equipment environment by leaning into handpiece growth, OEM diversification, and cost discipline. While these levers are offsetting some headwinds, margin compression and cash burn remain critical watchpoints. The company’s long-term positioning in body contouring and global expansion opportunities could provide upside if macro and regulatory conditions improve.
Industry Read-Through
APYX’s results underscore a broader trend in the aesthetic and surgical device market: capital equipment demand remains weak, but recurring consumables and OEM supply relationships are providing stability for those with diversified models. Providers with strong clinical evidence and surgeon engagement are better positioned to maintain utilization rates even as new equipment sales slow. For the sector, margin risk from mix shifts is a key theme, and companies lacking a robust recurring revenue stream may face greater volatility. The ongoing rise of body contouring and post-weight loss procedures, driven by GLP-1 adoption and changing patient demographics, remains an important secular tailwind for the category.